ReviewPublished 15 September 2026The future directions of CAR-T Cell therapy: unlocking the potential of immunotherapy in cancer treatmentAngel Alberto Justiz-Vaillant · Sachin Soodeen · Rodolfo Arozarena-Fundora · Patrick Eberechi Akpaka · Chandrashekhar UnakalFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1931159
Original ResearchPublished 3 September 2026Clinical phenotypes, endotypes, and biomarker profiles of immediate rituximab hypersensitivity reactions: a prospective pharmacovigilance studyNarapong Yotinnoratham · Wannada Laisuan · Kumutnart Chanprapaph · Silada Kanokrungsee · Chavachol Setthaudom · Supornchai Onpun · Pungjai Mongkolpathumrat · Supranee Buranapraditkun · Apinya Chungcharoenpanich · Nichapha Dechapaphapitak · Supa Oncham · Nattakirana Tongdee · Sananya Khamkaew · Ratchaya Lertnawapan · Jettanong KlaewsongkramFrontiers in Allergydoi 10.3389/falgy.2026.1903523
Mini ReviewPublished 15 April 2026CAR T cell engineering approaches to minimise toxicitiesElizabeth Hogben · Anna Schurich · Charlotte GrahamExperimental Biology and Medicinedoi 10.3389/ebm.2026.11021
Molecular MedicinePublished 18 September 2024DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndromeGrace Haroun · Erlinda M. GordonFrontiers in Molecular Medicinedoi 10.3389/fmmed.2024.1461151
